Falk, Stephen
At Bristol
3 papers on CoChatORCID 0000-0001-6106-3062
Most cited papers
- Verified
Systemic Chemotherapy with or without Cetuximab in Patients with Resectable Colorectal Liver Metastasis (New EPOC): Long-Term Results of a Multicentre, Randomised, Controlled, Phase 3 Trial
Bridgewater, J. A., Pugh, S. A., Maishman, T., Eminton, Z., Mellor, J., Whitehead, A., Stanton, L., Radford, M., Corkhill, A., Griffiths, G. O., et al. (2020) · The Lancet Oncology
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 255
- Verified
Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): the GO2 phase III trial
Hall, P. S., Swinson, D., Waters, J. S., Wadsley, J., Falk, S., Roy, R., Tillett, T., Nicoll, J., Cummings, S., Grumett, S. A., et al. (2019) · Journal of Clinical Oncology
Frailty in Older AdultsGastric Cancer Management and Outcomes
Cited by 59
- Verified
Tepotinib plus cetuximab in patients (pts) with RAS/BRAF wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to MET amplification (METamp).
Tabernero, J., Van Cutsem, E., Prausová, J., Isambert, N., Neuzillet, C., Siena, S., Pietrantonio, F., Falk, S., Wainberg, Z. A., Raghav, K. P. S., et al. (2021) · Journal of Clinical Oncology
Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations
Cited by 4
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free